Hyperbaric oxygen therapy treats late radiation injury by dissolving oxygen directly into blood plasma, bypassing the small vessels radiation destroys and stimulating new ones to grow. It is FDA-cleared and UHMS-approved for late radiation tissue injury, usually delivered over 30 to 40 sessions at 2.0 to 2.4 ATA, and covered by Medicare. The evidence is strongest for radiation cystitis, where a systematic review of 815 patients reported an 87.3% overall response, and genuinely mixed for preventing osteoradionecrosis, where the largest randomized trial found no benefit.
What is late radiation injury?
Late radiation injury is tissue damage that appears six or more months after radiotherapy ends, driven by progressive loss of small blood vessels rather than acute inflammation. Radiation causes endarteritis obliterans: vessel walls thicken, blood flow falls, and the tissue becomes chronically hypoxic, hypocellular, and hypovascular. This is the triad Marx described as the basis of osteoradionecrosis (Marx, 1983).
Acute radiation effects like mucositis and skin reactions happen during treatment and usually resolve within weeks. Late injury is a separate process. The tissue can look healed on the surface while it slowly loses the vascular supply it needs to maintain itself, so it breaks down after minor trauma, surgery, or a dental extraction and then fails to heal. Because the vascular loss is progressive, late injury can appear years or even decades after cancer treatment, and it can keep worsening without intervention (Delanian and Lefaix, 2004). Modern intensity-modulated radiotherapy has lowered the risk of the most feared complication, jaw osteoradionecrosis, to around 4% to 5% in recent series (Owosho et al., 2017).
Late injury presents differently by site. After pelvic radiation for prostate, cervical, or rectal cancer, it shows up as radiation cystitis (bladder bleeding and urgency) or proctitis (rectal bleeding and bowel dysfunction). After head and neck radiation it appears as osteoradionecrosis of the jaw or soft tissue breakdown affecting speech, eating, and reconstruction. Anywhere in a treatment field it can cause non-healing soft tissue necrosis or fistulas between organs. These injuries are chronic, often painful, and can dominate a survivor’s quality of life long after the cancer itself is gone, which is why an effective treatment for the underlying ischemia matters (Pasquier et al., 2004).
How does HBOT treat radiation damage?
HBOT addresses the vascular root of late radiation injury rather than the symptoms. Breathing 100% oxygen at 2.0 to 2.4 ATA raises dissolved plasma oxygen enough to reach tissue the damaged capillaries can no longer supply. Repeated sessions trigger angiogenesis, growing new vessels into the irradiated bed and partially rebuilding the blood supply radiation removed (Feldmeier and Hampson, 2002).
Most other treatments for late radiation injury manage the consequences: cauterizing a bleeding bladder, draining an abscess, controlling pain. HBOT targets the ischemia underneath. The oxygen gradient each session creates stimulates vascular endothelial growth factor and recruits progenitor cells, and over a full course this raises the vascular density of chronically ischemic tissue. That is the mechanism behind its FDA clearance and its formal listing by the Undersea and Hyperbaric Medical Society as an approved indication for delayed radiation injury. The effect is real but partial, and it works best in tissue that is ischemic and still viable rather than already dead (Feldmeier and Hampson, 2002).
Which radiation injuries respond to HBOT?
Radiation cystitis has the best evidence, followed by soft tissue radionecrosis and surgical wound support. Radiation proctitis and established osteoradionecrosis show moderate benefit, while HBOT to prevent osteoradionecrosis before dental work is genuinely contested after two randomized trials found no benefit. The table below grades each indication against the trial evidence.
HBOT for Radiation Injury: Indication, Protocol, and Evidence
| Radiation injury | Typical protocol | Reported outcome | Evidence grade | Insurance |
|---|---|---|---|---|
| Radiation cystitis | 30 to 40 sessions, 2.0 to 2.4 ATA | 87.3% overall, 65.3% complete response (Villeirs 2020); improved symptoms in RCT (RICH-ART 2019) | Strong | Covered |
| Soft tissue radionecrosis | 30 to 40 sessions, 2.0 to 2.4 ATA | Large reduction in head and neck wound dehiscence (Cochrane 2023) | Moderate | Covered |
| Radiation proctitis | 30 to 40 sessions, 2.0 to 2.4 ATA | 32% absolute healing gain, NNT 3 (Clarke 2008); no benefit for broader bowel dysfunction (HOT2 2016) | Moderate | Covered |
| Osteoradionecrosis (established) | 30 pre / 10 post-surgery (Marx protocol) | Adjunct to surgery; one RCT stopped for worse HBOT outcomes (Annane 2004) | Moderate | Covered |
| Radiation-induced fistula | 30 to 40 sessions plus surgical repair | Used to prepare tissue before closure; case-series level evidence (Hoggan 2014) | Emerging | Case-by-case |
| Pre-dental ORN prevention | 20 to 30 sessions before extraction | 5.4% vs 29.9% ORN (Marx 1985); no benefit in the largest RCT (HOPON 2019) | Contested | Case-by-case |
Radiation cystitis
Bladder damage after pelvic radiation causes urgency, frequency, pain, and bleeding. This is the best-supported HBOT radiation indication. A systematic review of 20 studies and 815 patients found a weighted overall response of 87.3% and complete response of 65.3% (Villeirs et al., 2020). The randomized RICH-ART trial found HBOT improved urinary symptoms and quality of life versus standard care (Oscarsson et al., 2019), and a long-term follow-up reported durable benefit at more than a decade (Nakada et al., 2012). Our dedicated radiation cystitis article covers protocols in detail.
Radiation proctitis and pelvic injury
Rectal damage from pelvic radiation causes bleeding, urgency, and bowel dysfunction. The evidence is split. A double-blind crossover RCT found HBOT produced a 32% absolute improvement in healing with a number-needed-to-treat of 3 for refractory proctitis (Clarke et al., 2008), and a meta-analysis of pelvic gastrointestinal complications favored HBOT for rectal bleeding (Yuan et al., 2020). The larger HOT2 trial, however, found no benefit across a broad range of chronic bowel symptoms after pelvic radiotherapy (Glover et al., 2016). HBOT is most reasonable for refractory bleeding, less so for general bowel dysfunction.
Osteoradionecrosis
Osteoradionecrosis is death of irradiated bone, most often the mandible. For established disease, HBOT is used alongside surgical debridement and reconstruction using the staged Marx protocol of pre- and post-operative sessions (Marx, 1983). The evidence here is moderate and debated: a randomized trial in overt mandibular osteoradionecrosis was stopped early for worse outcomes in the HBOT arm (Annane et al., 2004), while institutional guidelines still support selective use with surgery (Sultan et al., 2017). Our bone healing article goes deeper on protocols.
Soft tissue necrosis and fistulas
Radiation can break down soft tissue anywhere in the field, including the chest wall, breast, head and neck, and pelvis. The 2023 Cochrane review found HBOT may produce a large reduction in wound dehiscence after head and neck soft tissue surgery (Lin et al., 2023), and a systematic review of 41 studies supported its use for non-neurological soft tissue radiation injury with a low serious-adverse-event rate (Hoggan et al., 2014). For radiation-induced fistulas, HBOT is used to improve tissue quality before and after surgical radiation damage repair, though the evidence is case-series level.
How does HBOT compare with other treatments for radiation injury?
HBOT is one tool among several, and it is rarely used alone. For late radiation injury the main alternatives are targeted medical therapy, antifibrotic drug combinations, and surgery, chosen by injury type and severity. HBOT is distinctive because it treats the underlying ischemia rather than the symptom, but it is the most time-intensive option and its evidence is stronger for some injuries than others.
For radiation-induced fibrosis, the combination of pentoxifylline and vitamin E (tocopherol), sometimes with clodronate as the PENTOCLO regimen, can partially reverse the fibroatrophic process and is far less resource-intensive than a 40-session HBOT course (Delanian and Lefaix, 2004). For bleeding radiation cystitis, options range from bladder irrigation and cauterization to HBOT, with HBOT reserved for refractory cases where it has the strongest response data (Villeirs et al., 2020). For osteoradionecrosis, surgery to remove dead bone is central, and HBOT is an adjunct whose value is debated (Sultan et al., 2017). A radiation oncologist and the relevant specialist should sequence these, since the best results often come from combining them rather than choosing one.
Timing matters too. A randomized trial of early HBOT during and after head and neck radiotherapy improved quality-of-life scores for swallowing, dry mouth, and mouth pain (Teguh et al., 2009), pointing to a possible role beyond treating established injury, though this is not yet a standard indication.
How many HBOT sessions for radiation injury?
A standard course is 30 to 40 sessions at 2.0 to 2.4 ATA, each lasting 90 minutes, five days a week. Severe or extensive injuries can require 60 or more. For osteoradionecrosis managed surgically, the Marx protocol combines roughly 30 pre-operative and 10 post-operative sessions around the procedure (Marx, 1983).
The course is longer than most HBOT indications because rebuilding vasculature takes repeated exposures over weeks. Progress is tracked throughout. Our session guide explains what each visit involves, and the what to expect article helps patients prepare. Detailed outcome data by injury type is compiled on our radiation injury outcomes page.
Does insurance cover HBOT for radiation injury?
Yes. Late radiation tissue injury is one of the best-covered HBOT indications. Medicare covers it under CMS National Coverage Determination 20.29 with documentation of radiation history, the injury, and a prior treatment attempt, and most commercial insurers follow Medicare policy.
Soft tissue and bony radiation necrosis are named covered indications in the national coverage determination and in the UHMS approved list. Coverage is most straightforward for cystitis, proctitis, soft tissue necrosis, and established osteoradionecrosis; purely preventive pre-dental HBOT is more often reviewed case by case, partly because recent trial evidence is mixed. Our insurance guide explains prior authorization, and the cost guide covers out-of-pocket scenarios when coverage is incomplete.
Can HBOT prevent osteoradionecrosis before dental work?
This was long-standing practice, but it is now contested. The original evidence was a 1985 randomized trial in which pre-extraction HBOT cut osteoradionecrosis from 29.9% to 5.4% versus antibiotics (Marx et al., 1985). That result drove decades of prophylactic use before dental extractions in irradiated jaws.
Recent trials have not confirmed it. The multicenter HOPON randomized trial found no difference in osteoradionecrosis at six months between HBOT and control (6.4% versus 5.7%) after dental surgery in irradiated mandibles (Shaw et al., 2019). A systematic review found the overall osteoradionecrosis rate after extraction was about 7%, falling only modestly to 4% with prophylactic HBOT (Nabil and Samman, 2011). Part of the reason the older numbers no longer hold is that modern intensity-modulated radiotherapy has lowered baseline osteoradionecrosis risk (Owosho et al., 2017). The current picture: pre-dental HBOT may still be considered for the highest-risk patients (high radiation dose to the mandible, extensive surgery), but it is no longer a routine recommendation for every irradiated patient needing an extraction. Discuss individual risk with your oncologist and oral surgeon.
When does HBOT not work?
HBOT does not help tissue that is already dead rather than ischemic, because there are no living cells to respond to the oxygen. Active cancer in the treatment field is a contraindication, and most centers require oncologist confirmation of no active disease before starting. Advanced injuries may need surgical reconstruction rather than HBOT alone.
Several factors blunt the response. Smoking constricts vessels and impairs the angiogenic effect, so it should be stopped before and during treatment. Poorly controlled diabetes adds complexity. And the evidence itself sets limits: HBOT did not help general bowel dysfunction in HOT2, did not prevent osteoradionecrosis in HOPON, and was harmful in one osteoradionecrosis treatment trial (Annane et al., 2004). Honest counseling means matching HBOT to the indications where trials support it, chiefly radiation cystitis and soft tissue necrosis, and setting realistic expectations elsewhere. HBOT is one of several FDA-cleared HBOT indications, and it overlaps with the evidence base for wound healing.
How long after radiation can late injury appear?
Late radiation injury is defined as appearing six or more months after radiation ends, but many cases emerge years or even decades later. The underlying vascular loss is progressive and has no fixed timeline, and stress on irradiated tissue, such as surgery, trauma, or a dental extraction, can trigger breakdown long after treatment (Delanian and Lefaix, 2004).
Can HBOT be used while I am still receiving cancer treatment?
Active malignancy in the treatment field is generally a contraindication, and most centers require oncologist confirmation that active disease is not present before starting HBOT for radiation injury (Feldmeier and Hampson, 2002). If you are on maintenance therapy with no active disease, your oncology team and the hyperbaric physician should review your specific situation before proceeding.
Does HBOT reverse osteoradionecrosis on its own?
No. For established osteoradionecrosis, HBOT is an adjunct to surgical debridement and reconstruction, not a standalone cure, and its benefit is debated. One randomized trial was stopped for worse outcomes in the HBOT arm (Annane et al., 2004), while institutional guidelines still support selective use alongside surgery in appropriate patients (Sultan et al., 2017). It is not a substitute for surgical management of dead bone.
Sources
- Lin ZC, Bennett MH, Hawkins GC, Azzopardi CP, Feldmeier J, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023;8(8):CD005005. DOI: 10.1002/14651858.CD005005.pub5
- Clarke RE, Tenorio LMC, Hussey JR, et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys. 2008;72(1):134-143. PMID 18342453
- Glover M, Smerdon GR, Andreyev HJ, et al. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial. Lancet Oncol. 2016;17(2):224-233. PMID 26703894
- Oscarsson N, Muller B, Rosen A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019;20(11):1602-1614. PMID 31537473
- Nakada T, Nakada H, Yoshida Y, et al. Hyperbaric oxygen therapy for radiation cystitis in patients with prostate cancer: a long-term follow-up study. Urol Int. 2012;89(2):208-214. PMID 22797611
- Villeirs L, Tailly T, Ost P, et al. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: systematic review of the recent literature. Int J Urol. 2020;27(2):98-107. DOI: 10.1111/iju.14130
- Yuan JH, Song LM, Liu Y, et al. The effects of hyperbaric oxygen therapy on pelvic radiation induced gastrointestinal complications (rectal bleeding, diarrhea, and pain): a meta-analysis. Front Oncol. 2020;10:390. PMID 32328454
- Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5):283-288. PMID 6572704
- Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc. 1985;111(1):49-54. PMID 3897335
- Shaw RJ, Butterworth CJ, Silcocks P, et al. HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): a randomized controlled trial of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible after dentoalveolar surgery. Int J Radiat Oncol Biol Phys. 2019;104(3):530-539. PMID 30851351
- Annane D, Depondt J, Aubert P, et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group. J Clin Oncol. 2004;22(24):4893-4900. PMID 15520052
- Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. Int J Oral Maxillofac Surg. 2011;40(3):229-243. PMID 21115324
- Owosho AA, Tsai CJ, Lee RS, et al. The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with IMRT: the Memorial Sloan Kettering Cancer Center experience. Oral Oncol. 2017;64:44-51. DOI: 10.1016/j.oraloncology.2016.11.015
- Sultan A, Hanna GJ, Margalit DN, et al. The use of hyperbaric oxygen for the prevention and management of osteoradionecrosis of the jaw: a Dana-Farber/Brigham and Women’s Cancer Center multidisciplinary guideline. Oncologist. 2017;22(3):343-350. PMID 28209748
- Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med. 2002;29(1):4-30. PMID 12507182
- Hoggan BL, Cameron AL. Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries. Support Care Cancer. 2014;22(6):1715-1726. PMID 24794980
- Teguh DN, Levendag PC, Noever I, et al. Early hyperbaric oxygen therapy for reducing radiotherapy side effects: early results of a randomized trial in oropharyngeal and nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2009;75(3):711-716. PMID 19386439
- Andren J, Enblad P, Hedlund A, et al. An observational trial to establish the effect of hyperbaric oxygen treatment on pelvic late radiation tissue injury due to radiotherapy. Diving Hyperb Med. 2020;50(3):250-256. PMID 32957127
- Pasquier D, Hoelscher T, Schmutz J, et al. Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiother Oncol. 2004;72(1):1-13. PMID 15236869
- Delanian S, Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol. 2004;73(2):119-131. PMID 15542158
- Dejonckheere CS, et al. Hyperbaric oxygen therapy for chronic radiotherapy-related adverse effects: a clinically focused review. CA Cancer J Clin. 2026. DOI: 10.3322/caac.70058
- Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Hyperbaric Oxygen Therapy (20.29). CMS Medicare Coverage Database
- Undersea and Hyperbaric Medical Society. Delayed Radiation Injury (Soft Tissue and Bony Necrosis). UHMS Approved Indications, 14th Edition. UHMS Approved Indications
- U.S. Food and Drug Administration. Hyperbaric Oxygen Therapy: Get the Facts. 2021. FDA Consumer Update
- Mayo Clinic. Hyperbaric oxygen therapy. Mayo Clinic Patient Guide
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
